Article
GlaxoSmithKline expands its cancer scope with $1.9B Sierra Oncology acquisition - MedCity News
Rating:
0.0
Views:
61
Likes:
1
Library:
1
GlaxoSmithKline is further building out its cancer drug portfolio by acquiring Sierra Oncology, a biotech whose FDA-ready myelofibrosis drug has clinical data showing advantages over a blockbuster product marketed by Incyte. The deal comes as GSK prepares a spinoff of its consumer products as part of a broader strategy to hone its focus on specialty medicines and vaccines.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value